Microbiologist looking down a microscope in a lab

UK awards first Innovation Passport to promising treatment

A promising treatment for a cancer-causing rare disease is set to become the first innovative medicine in the UK to be awarded an ‘Innovation Passport’ under a new national approval process.

The Innovative Licensing and Access Pathway (ILAP) has been established to reduce the time to market for innovative treatments, supporting quicker development and access to cutting-edge medicines.

Belzutifan has become the first to be awarded approval under the ILAP process; a treatment developed for adults with von Hippel Lindau (a rare genetic disorder that causes cancer).

Innovation Passports, as the ILAP approval has been colloquially called, are approved by the Medicines and Healthcare products Regulatory Agency (MHRA), the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC).

The approval of belzutifan through this process means patients could benefit much sooner from the potentially transformative treatment, and will see it accelerated through the approval process.

The ILAP was launched back in January, but this is the first award given under it.

As part of the ILAP approval process, potential innovative medicines must still work to the MHRA’s globally-recognised high standards of quality and safety, but will benefit from improved flexibility to reduce the time it takes for these treatments to be available to NHS patients.

Dr June Raine CBE, Chief Executive of the MHRA, said: “We’re transforming the MHRA to make the regulator an enabler of innovation. I’m very pleased to announce the first Innovation Passport designation demonstrating that this process is well underway.

“Our Innovative Licensing and Access Pathway is already working to deliver new and innovative treatments to patients through strong and effective partnerships.

“Patients are our top priority and are involved at every stage of this process.

“Together, we look forward to bringing more Innovation Passport holders on board to deliver earlier access to these products, better outcomes for patients and to continue our transformation.”

Chief Executive of the ABPI, Richard Torbett, said: “It’s great to see the ILAP moving forward quickly with the award of the first innovation passport.

“Now the MHRA is a sovereign medicines regulator, this scheme is a really positive sign that the UK is serious about accelerating the approval of innovative new medicines, which is a win for patients, the NHS and industry.

“We look forward to seeing medicines coming through this scheme and getting to the people who need them as quickly as possible.”

NHE Jan.Feb 21

NHE Jan/Feb 21

Creating a net zero NHS

NHE’s Jan/Feb 2021 edition focuses on the role of pharma working alongside the NHS, how we are working to digitise the health service and the ways in which the NHS can be involved in addressing the climate emergency.


View all videos
BMC Whitepaper


How well do the NHS understand digital potential?

Recently we have been gathering primary data direct from those within the NHS on modernising NHS technology and the challenges faced around resource, training and service management.

Download the full whitepaper and read the full findings in our exclusive report to learn more.

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all